Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:03:51.642Z.
Calculation as of: 2026-10-06T17:03:51.642Z.
Quote observation: 2026-10-06T17:00:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 54b27289092361ea6502e61cba635145b9acb525321868e00b72fceafc9e89d3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.72B
EBITDA Yield
22.53%
TTM Avg
15.05%
3Y Avg
6.70%
5Y Avg
7.30%
Market Cap
$1.75B
EBITDA Yield
10.40%
TTM Avg
9.93%
3Y Avg
8.18%
5Y Avg
7.57%
Market Cap
$1.76B
EBITDA Yield
2.55%
TTM Avg
2.78%
3Y Avg
2.43%
5Y Avg
2.43%
Market Cap
$1.64B
EBITDA Yield
1.75%
TTM Avg
1.16%
3Y Avg
1.16%
5Y Avg
1.16%
Market Cap
$1.78B
EBITDA Yield
6.09%
TTM Avg
1.74%
3Y Avg
1.49%
5Y Avg
1.49%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Personalis, Inc. (PSNL) | $1.71B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.72B | 22.53% | 15.05% | 6.70% | 7.30% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 10.40% | 9.93% | 8.18% | 7.57% |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.76B | 2.55% | 2.78% | 2.43% | 2.43% |
| Septerna Inc (SEPN)vs › | $1.65B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 1.75% | 1.16% | 1.16% | 1.16% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.78B | 6.09% | 1.74% | 1.49% | 1.49% |
| Absci Corporation (ABSI)vs › | $1.79B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 14.84% | 10.69% | 8.08% | 6.99% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
